Background: The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. Methods: We accessed Ethiopian Universities' online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger's regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. Results: The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6-20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9-13.6%), 5.6% (95% confidence interval: 2.9-8.3%), and 6.3% (95% confidence interval: 4.6-8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3-2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2-2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3-11.8) on HIV treatment failure were estimated. Conclusions: Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence. Protocol registration: It has been registered in the PROSPERO database with a registration number of CRD42018100254.

Background:The pooled burden of HIV treatment failure and its associated factors in Ethiopian context is required to provide evidence towards renewed ambitious future goal.Methods: Ethiopian Universities' (University of Gondar and Addis Ababa University) online repository library, Google scholar, PubMed, Web of Science, and Scopus were used to get the research articles. I-squared statistics was used to see heterogeneity. Publication bias was checked by Egger's regression test. The DerSimonian-Laird random effects model was employed to estimate the overall prevalence. Subgroup analysis based on geographical location of the study, study population by age, treatment failure type, and study design was conducted to see variation in outcomes. The sensitivity analysis was also employed to see whether the outlier result found in the included studies.

Background:The bacteria most likely to cause bacteremia include Staphylococcus, Streptococcus, Enterococcus, Escherichia, Klebsiella, Pseudomonas, Enterobacter, Haemophilus, and Neisseria genera. Bloodstream infections remain one of the most important causes of morbidity and mortality throughout the world. Drug-resistant pathogens are becoming the most challenging problem and they have different economic and social impacts around the world. Objective: To study the bacterial profile and antibiotic susceptibility among bacteremiasuspected patients in the University of Gondar Teaching Hospital from September 2003 to February 2013. Materials and method: This retrospective cross-sectional study was conducted from March to May 2013 at the University of Gondar. Data were collected and extracted manually from the microbiology registration books of the hospital laboratory using checklists and were checked for its completeness and consistency. Result: Among a total of 856 blood samples analyzed, 169 (19.7%) cases were bacteremia confirmed. From the confirmed cases, 98 (58%) were male and 71 (42%) female. Culture positivity rate was highest (44%) in the age group of ≤28 days followed by the age group of 29 days-5 years. Conclusion: In our study, coagulase-negative staphylococci were the most common causative agent for bacteremia among the Gram-positive isolates. The overall antimicrobial susceptibility pattern of the Gram-positive isolates was an intermediate level of resistance (60%-80%), but Gram-negative bacteria showed a high level of resistance (>80%) against ampicillin and amoxicillin.

A human immunodeficiency virus (HIV) test during pregnancy is the gateway to the prevention of mother-to-child transmission (PMTCT) of HIV. Estimating the national uptake of HIV tests among pregnant women is an important course of action. Thus, we pooled the information about the national uptake of HIV tests and determined the significant factors among pregnant women in Ethiopia. Methods: We searched PubMed, Scopus, Web of Science, and Google Scholar databases. We also searched for cross-references to get additional relevant studies, and included cross-sectional, case-control and cohort study studies. We applied a random-effects model meta-analysis to pool the national data of uptake of HIV tests. Galbraith's plot and Egger's regression test were employed to check publication bias, and heterogeneity was assessed using I ² statistics. The protocol registered is found in the PROSPERO database with the registration number CRD42019129166. Results: In total, 22 articles with 13 818 pregnant women study participants were involved. The national uptake of HIV tests among pregnant women was 79.6% (95% CI 73.9-85.4). Living in urban areas (AOR 2.8; 95% CI 1.1-4.6), previous HIV tests (AOR 4.6; 95% CI 1.2-8.0), and comprehensive knowledge on mother-to-child transmission (MTCT) (AOR 2.61; 95% CI 1.5-3.7) and PMTCT of HIV (AOR 2.1; 95% CI 1.5-2.8) were associated with increased practice of HIV tests. Conclusion: This review showed that HIV test coverage among pregnant women was approximately 80% and substantially lower than the national recommendation. Addressing HIV-related health services for rural women and providing health information on MTCT and PMTCT of HIV to increase HIV testing coverage is required.

Background: The national burden of HIV treatment failure and associated factors in Ethiopian context is required to provide evidence towards a renewed ambitious future goal.Methods: We accessed Ethiopian Universities’ online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger’s regression test. The pooled prevalence was estimated using DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. Results: The overall HIV treatment failure was 15.9% (95% CI: 11.6%-20.1%). Using immunological, virological, and clinical definition, HIV treatment failure was 10.2% (6.9%-13.6%), (5.6% (95% CI: 2.9%-8.3%), and (6.3% (4.6%-8.0%)), respectively. The pooled effects of WHO clinical stage III/IV (AOR=1.9; 95% CI: 1.3-2.6), presence of opportunistic infections (AOR=1.8; 95% CI: 1.2-2.4), and poor HAART adherence (AOR= 8.1; 95% CI: 4.3-11.8) on HIV treatment failure were estimated. Conclusions : HIV treatment failure in Ethiopia found to be high. HIV intervention programs need to address the specified contributing factors of HIV treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain HIV treatment adherence. Protocol Registration : It has been registered in the PROSPERO database with a registration number of CRD42018100254.